Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2024

Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26

RRID:AB_2143884 Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 3077, RRID:AB_2143884)

Antibody Information

URL: http://antibodyregistry.org/AB_2143884

Proper Citation: (Cell Signaling Technology Cat# 3077, RRID:AB_2143884)

Target Antigen: Met, phospho (Tyr1234 / Tyr1235)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10328091, AB_10329175, AB_2143884, AB_2235289, AB_2315156.

Antibody Name: Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26

Description: This monoclonal targets Met, phospho (Tyr1234 / Tyr1235)

Target Organism: human, mouse, rat

Clone ID: Clone D26

Antibody ID: AB_2143884

Vendor: Cell Signaling Technology

Catalog Number: 3077

Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26.

No alerts have been found for Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer research communications, 4(2), 337.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. Cell reports. Medicine, 5(2), 101388.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(5), 943.

Kha M, et al. (2023) The injury-induced transcription factor SOX9 alters the expression of LBR, HMGA2, and HIPK3 in the human kidney. American journal of physiology. Renal physiology, 324(1), F75.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified nonsmall cell lung cancer. British journal of cancer.

Miyake K, et al. (2023) A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. Cell reports, 42(7), 112688.

Lin ZS, et al. (2023) EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. eLife, 12.

Zuo Q, et al. (2023) Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. Cell reports, 42(3), 112164.

Carbonaro M, et al. (2023) IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Science advances, 9(15), eadf4490.

Wu F, et al. (2023) Immunological profiles of human oligodendrogliomas define two distinct

molecular subtypes. EBioMedicine, 87, 104410.

Reischmann N, et al. (2023) Overcoming MET-mediated resistance in oncogene-driven NSCLC. iScience, 26(7), 107006.

Hino N, et al. (2022) A feedback loop between lamellipodial extension and HGF-ERK signaling specifies leader cells during collective cell migration. Developmental cell, 57(19), 2290.

Hagege A, et al. (2022) Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell reports. Medicine, 3(9), 100659.

Kajiwara K, et al. (2022) Src activation in lipid rafts confers epithelial cells with invasive potential to escape from apical extrusion during cell competition. Current biology : CB, 32(16), 3460.

Kim J, et al. (2022) KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1+ stem cells. Cell reports, 40(3), 111077.

Shao WQ, et al. (2022) Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell reports, 39(3), 110712.

Pathmanathan S, et al. (2022) B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. iScience, 25(11), 105419.

Komatsu Y, et al. (2021) De novo peptide grafting to a self-assembling nanocapsule yields a hepatocyte growth factor receptor agonist. iScience, 24(11), 103302.

Kim M, et al. (2021) A MET-PTPRK kinase-phosphatase rheostat controls ZNRF3 and Wnt signaling. eLife, 10.

Bi J, et al. (2021) Targeting glioblastoma signaling and metabolism with a re-purposed brainpenetrant drug. Cell reports, 37(5), 109957.